Myeloma Minute: ASH 2018: That's a Wrap!


| INSPIRATION | Latest Research


Watch a Replay of the IMWG Conference Series, “Making Sense of Treatment”

Watch a replay of the IMF's popular IMWG Conference Series, "Making Sense of Treatment." Recorded at the 2018 American Society of Hematology (ASH) annual meeting and exposition, this replay features IMF Chairman Dr. Brian G.M. Durie, Dr. María-Victoria Mateos from the University of Salamanca, Spain, and IMF Chief Medical Officer Dr. Joseph Mikhael. During this 60-minute webcast, these multiple myeloma experts distilled and debated the latest news and trends in the treatment of the disease.


| ACTION | Easy Ways to Give


| ACTION | Holiday Giving


You Shop. Amazon Gives.
Give the Gift of the Season

Make your holiday purchases with a purpose this year. When you shop at and select the International Myeloma Foundation as your charity, Amazon donates a portion of your purchase to the IMF, at no added cost to you. It’s a win-win!

The IMF appreciates your contributions year-round. With December, we know that much of your energy may be focused on the spirit of giving. We encourage you to “Give the Gift of the Season” and raise multiple myeloma awareness at the same time. Here’s how: If you have a Facebook profile, set up a giving campaign to donate the holidays to the IMF—specifically Hanukkah, Christmas, and/or Kwanzaa. Follow the 10 Easy Steps at the link below to set up your own Donate the Holidays campaign on your personal Facebook page, encouraging your Facebook friends to give. We thank you for all you do and wish you a safe and happy holiday!



| ACTION | CMS Proposal


CMS Proposal Would Weaken Access to Drugs in Medicare’s Six Protected Classes

On November 26, 2018, the Centers for Medicare and Medicaid Services (CMS) proposed a rule that IMF’s Advocacy Team believes could dramatically impact the ability of patients with Medicare Part D to access their medications. If enacted, the rule, “Modernizing Medicare Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses,” would impact Medicare’s six protected classes, in addition to Medicare Part B.

In particular, the administration proposes to change Medicare’s six protected class policy. This policy requires the coverage of most of the drugs in these six protected classes. These drugs are typically used to treat many of the most ill patients, including some drugs used to fight cancer. The administration claims that by providing plans with flexibility, Part D Plans will be able to better negotiate for discounts on drugs. Thereby, these Part D plans will be able to offer lower-cost drugs to patients.

However, Robin Roland Levy, IMF’s Senior Director of Public Policy and Advocacy says, “While the IMF supports the administration’s efforts to reduce patient out-of-pocket expenses, we believe this particular proposal will significantly weaken patient access to drugs in Medicare’s six protected classes and that it will be extremely burdensome to multiple myeloma patients and their medical practitioners.” The IMF will continue to monitor and comment on this proposed rule and its effects on multiple myeloma patients.


| INNOVATION | ASH Symposium


Catch a Replay of the Satellite Symposium from the 60th ASH Annual Meeting & Exposition

The International Myeloma Foundation and Clinical Care Options co-sponsored symposium featured an esteemed panel of international experts at the 60th ASH annual meeting and exposition. Listen to a replay of these doctors offering their perspectives on practice-changing data and optimal management of patients with multiple myeloma.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Nancy's Passion for Patients

Ongoing Fundraiser
Moseman’s 50th Anniversary

March 15-16, 2019
IMF Patient & Family Seminar
Boca Raton, FL

April 5-6, 2019
IMF Patient & Family Seminar
Short Hills, NJ

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.